RayzeBio’s IPO will support pivotal testing of a targeted radiopharmaceutical for cancer patients who progress after treatment with Novartis’s Lutathera. Neumora will apply its IPO cash toward Phase 3 testing of a depression drug with a novel mechanism of action.
-Biopharmaceutical firm Neumora Therapeutics, backed by Amgen and Japan s SoftBank, is aiming to raise up to $264.8 million in its U.S. initial public offering, according to a regulatory filing on. -Today at 06:29 am- MarketScreener
Biopharmaceutical firm Neumora
Therapeutics, backed by Amgen and Japan s SoftBank
, is aiming to raise up to $264.8 million in its U.S.
initial public offering, according to a regulatory filing.
SoftBank-backed Neumora seeks $2 74 bln valuation in US IPO kitco.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kitco.com Daily Mail and Mail on Sunday newspapers.